Printed on 7/20/2026
For informational purposes only. This is not medical advice.
YMRS is a structured clinician rating scale for mania severity in bipolar-spectrum and related presentations. It is frequently used for baseline severity and longitudinal treatment-response tracking.
Formula: YMRS total = sum of 11 items with weighted items (max score 60).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
A trained clinician rates 11 items based on patient interview and direct behavioral observation covering the past 48 hours. Items assess elevated mood, increased motor activity, sexual interest, reduced sleep need, irritability, pressured speech, language and thought disorder, thought content (grandiosity/psychosis), disruptive behavior, appearance, and insight.
Seven items are scored 0-4 (elevated mood, motor activity, sexual interest, sleep, language/thought disorder, appearance, insight). Four items are weighted and scored 0-8 (irritability, speech rate/amount, thought content, disruptive/aggressive behavior). Sum all 11 items for a total of 0-60.
YMRS interpretation: 0-12 = absent/remission (euthymia); 13-20 = mild mania; 21-35 = moderate mania; above 35 = severe mania. YMRS 12 or below is the standard remission threshold in most bipolar clinical trials and treatment guidelines (CANMAT 2018).
Psychiatrists
YMRS is the standard clinician-administered mania severity scale for bipolar I disorder. It provides a reproducible, quantified measure of manic symptom burden across the 11 core mania domains, enabling objective comparison across visits and communication of severity between treatment providers.
Psychopharmacologists
All major FDA-approved antimanic medications (lithium, valproate, atypical antipsychotics) demonstrated efficacy via YMRS reduction in pivotal clinical trials. Serial YMRS monitoring every 1-2 weeks during acute mania treatment provides objective evidence of medication response or inadequate response requiring treatment escalation.
Clinical Researchers
YMRS is the FDA-required primary efficacy endpoint for all drug development in bipolar I mania. The 50% reduction in YMRS from baseline is the standard response criterion, while YMRS 12 or below is the remission criterion used universally in bipolar mania trials.
Inpatient Psychiatric Teams
YMRS is used to document objective mania severity for hospitalization decision-making, treatment intensity planning, and monitoring progress toward discharge readiness. YMRS above 35 (severe) typically indicates requirement for intensive inpatient treatment with rapid dose escalation.
Bipolar Care Teams
For bipolar patients in maintenance treatment, quarterly YMRS monitoring provides early detection of subclinical manic shifts (prodromal mania) before full episodes develop. Scores trending upward from baseline euthymia (0-12) can trigger early intervention including medication adjustment and behavioral strategies.
YMRS requires trained clinician administration based on structured interview and behavioral observation. It is not validated for self-report and must not be administered as a questionnaire. Clinician observation of motor behavior, speech, and appearance during the interview is integral to accurate scoring.
YMRS is specifically designed to assess symptom severity in the past 48 hours. Using a longer time frame (past week, past month) will produce unreliable scores. For longer-term mood tracking, use Clinical Global Impressions-Bipolar (CGI-BP) or the Life Chart Methodology.
Classic euphoric mania is not the only presentation. Dysphoric or irritable mania presents with elevated irritability (item 5) without euphoria (item 1 may score 0-1). Irritable mania is more common in women, in adolescents, and in bipolar II. Missing irritable mania is the most common clinical error in bipolar diagnosis.
YMRS item 8 (thought content) includes grandiosity, paranoia, religiosity, and frank psychotic delusions — not just delusions. Grandiose ideas short of full delusions score 2, paranoid ideas score 4, clear delusions score 6-8. Always probe all thought content domains during interview.
Item 7 (language/thought disorder) captures flight of ideas, tangentiality, and loose associations. High scores on both item 7 and item 8 (thought content) indicate manic psychosis and warrant antipsychotic treatment alongside mood stabilizers.
Insight (item 11) is one of the most clinically important items. Patients with mania typically have poor insight, denying illness and refusing medication. Poor insight (score 4) indicates high risk for medication non-adherence and need for involuntary treatment consideration.
YMRS 12 or below is the standard remission criterion in most bipolar clinical trials and is referenced in CANMAT 2018 bipolar I guidelines. Clinical treatment goal during acute mania management is achieving YMRS remission, not just response (50% reduction).
FDA-approved first-line options for bipolar I mania with YMRS-reduction evidence: lithium, valproate, aripiprazole, asenapine, cariprazine, olanzapine, quetiapine, risperidone, ziprasidone. The choice among these depends on side effect profile, polarity history, and individual patient factors.
DSM-5 allows a 'with mixed features' specifier when manic episodes include depressive symptoms. Combining YMRS with MADRS or Hamilton Depression Rating Scale (HDRS) enables quantification of both pole severity simultaneously, crucial for treatment planning (antipsychotics preferred over antidepressants in mixed states).
Electroconvulsive therapy (ECT) has strong evidence for severe mania with YMRS above 35 or treatment-resistant cases. ECT produces rapid YMRS reduction, often within 3-5 treatments, and is particularly valuable when pharmacotherapy is contraindicated or when rapid response is required.
YMRS published by Young et al. (Br J Psychiatry 1978) from 70 manic inpatients. Inter-rater reliability ICC 0.93. Internal consistency alpha 0.80. Widely used as the primary efficacy endpoint in bipolar mania clinical trials (FDA-required for drug approval). YMRS 12 or lower as remission threshold used in CANMAT 2018 bipolar guidelines. All major antimanic agents (lithium, valproate, atypical antipsychotics) demonstrated YMRS reduction in pivotal trials. CANMAT 2018 and BAP 2016 guidelines reference YMRS for mania severity staging.
Higher YMRS totals reflect greater manic symptom burden and can guide urgency and intensity of mood-stabilization planning.
Use in clinician-led bipolar/mania evaluation and serial monitoring contexts.
YMRS requires clinician training and consistent interviewing. It is severity-focused and does not independently establish full DSM diagnostic criteria.
For related assessments, see MDQ Screener, PHQ-9 and HAM-A.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Screen for bipolar-spectrum symptom patterns using the Mood Disorder Questionnaire (MDQ) criteria framework.
OpenMental HealthFree PHQ-9 depression screening questionnaire. Take the Patient Health Questionnaire-9 to assess depression severity with instant scoring and interpretation. Also screen for anxiety with [GAD-7](/tools/gad7).
OpenMental HealthRate clinician-observed anxiety severity using the 14-item Hamilton Anxiety Rating Scale.
Open